Genetic parameters of neuroblastomas

Cancer Letters

Volumn 184, Issue 2, 2002, Pages 127-147

  Westermann, Frank ^a   Schwab, Manfred ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

11q; 17q; 1p; Amplification; Apoptosis; Caspase; Chromosome; Genetic instability; Methylation; MYCN; Neuroblastoma; Oncogene; Pediatric tumors; Ploidy; Prognosis; Silencing; Tumor suppressor gene

Indexed keywords

CELL DNA; CYTOSTATIC AGENT; GAMMA INTERFERON; MESSENGER RNA; PROTEIN; PROTEIN MYCN; UNCLASSIFIED DRUG;

ADRENAL MEDULLA; ADRENERGIC SYSTEM; ALLELE; APOPTOSIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CELL MIGRATION; CHILDHOOD CANCER; CHROMOSOME 11Q; CHROMOSOME 17Q; CHROMOSOME 1P; CLINICAL TRIAL; CYTOGENETICS; FATALITY; GENE AMPLIFICATION; GENE DELETION; GENE LOSS; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; METASTASIS; NEURAL CREST; NEUROBLASTOMA; NEUROECTODERM TUMOR; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SHORT SURVEY; TUMOR DIFFERENTIATION;

EID: 0037190798     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00199-4     Document Type: Review

References (154)

1. The current contribution of molecular factors to risk estimation in neuroblastoma patients
2. Neuroblastoma: Current drug therapy recommendations as part of the total treatment approach
3. Why does stage 4s neuroblastoma regress spontaneously?
4. Spontaneous regression of stage IV neuroblastoma
5. Prolonged survival of a patient with disseminated neuroblastoma
6. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children
7. Screening for neuroblastoma in North America. 2-year results from the Quebec Project
8. Which cases are found and missed by neuroblastoma screening at 1 year? Results from the 1992 to 1995 study in three Federal States of Germany
9. Biology and genetics of human neuroblastomas
10. Clinical and biological aspects of neuroblastoma
11. Terminology and morphologic criteria of neuroblastic tumors: Recommendations by the International Neuroblastoma Pathology Committee
12. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma
13. Flow cytometric DNA analysis of neuroblastoma. Correlation with histology and clinical outcome
14. N-myc amplification in neuroblastomas: Histopathological, DNA ploidy, and clinical variables
15. Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma
16. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study
17. Different karyotypic patterns in early and advanced stage neuroblastomas
18. Disomy 1 with terminal 1p deletion is frequent in mass-screening-negative/late-presenting neuroblastomas in young children, but not in mass-screening-positive neuroblastomas in infants
19. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1
20. Prognostic significance of DNA di-tetraploidy in neuroblastoma
21. Comparative genomic hybridization (CGH) analysis of neuroblastomas - an important methodological approach in paediatric tumour pathology
22. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification
23. Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: How many genetic subgroups are there?
24. Comparative genomic hybridization study of primary neuroblastoma tumors. United Kingdom Children's Cancer Study Group
25. Comparative genomic hybridization analysis of human neuroblastomas: Detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines
26. Comparative genomic hybridization reveals changes in DNA-copy number in poor-risk neuroblastoma
27. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors
28. Mechanism and relevance of ploidy in neuroblastoma
29. Managing the centrosome numbers game: From chaos to stability in cancer cell division
30. Familial neuroblastoma. Case reports, literature review, and etiologic considerations
31. Mutation and cancer: Neuroblastoma and pheochromocytoma
32. A general theory of carcinogenesis
33. Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma
34. Exclusion of candidate genes and chromosomal regions in familial neuroblastoma
35. Familial predisposition to neuroblastoma does not map to chromosome band 1p36
36. Genomic instability in 1p and human malignancies
37. Chromosomal aberrations in human neuroblastomas
38. Cytogenetic features of human neuroblastomas and cell lines
39. Solid tumors of children: Chromosome abnormalities and the development of cancer
40. Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines
41. Dissociation of suppression of tumorigenicity and differentiation in vitro effected by transfer of single human chromosomes into human neuroblastoma cells
42. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: Correlation with N-myc amplification
43. Deletion mapping of chromosomes 14q and 1p in human neuroblastoma
44. Allelotype of neuroblastoma
45. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: A Children's Cancer Group study
46. Neuroblastoma consensus deletion maps to 1p36.1-2
47. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3
48. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas
49. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms
50. Constitutional translocation t(1;17)(p36;q12-21) in a patient with neuroblastoma
51. Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma
52. Detailed molecular analysis of 1p36 in neuroblastoma
53. Smallest region of overlapping deletion in 1p36 in human neuroblastoma: A 1 Mbp cosmid and PAC contig
54. A reciprocal translocation (1;15) (36.2;q24) in a neuroblastoma cell line is accompanied by DNA duplication and may signal the site of a putative tumor suppressor-gene
55. Identification and characterization of novel genes located at the t(1;15)(p36.2;q24) translocation breakpoint in the neuroblastoma cell line NGP
56. Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line
57. Chromosome 1p36 deletions: The clinical phenotype and molecular characterization of a common newly delineated syndrome
58. Terminal deletion of 1p36
59. Molecular refinement of the 1p36 deletion syndrome reveals size diversity and a preponderance of maternally derived deletions
60. Constitutional 1p36 deletion in a child with neuroblastoma
61. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma
62. Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma
63. Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: One probably imprinted, another associated with N-myc amplification
64. Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification
65. Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification
66. Clinical relevance of loss heterozygosity of the short arm of chromosome 1 in neuroblastoma: A single-institution study
67. Three chromosomal rearrangements in neuroblastoma cluster within a 300-kb region on 1p36.1
68. Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: An introduction
69. Preferential amplification of the paternal allele of the N-myc gene in human neuroblastomas
70. Analysis of genomic imprinting at 1p35-36 in neuroblastoma
71. Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma
72. Significance of chromosome 1p loss of heterozygosity in neuroblastoma
73. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma
74. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma
75. FISH analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations
76. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour
77. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
78. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc
79. MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells
80. Duplication of N-MYC at its resident site 2p24 may be a mechanism of activation alternative to amplification in human neuroblastoma cells
81. Germline duplication of chromosome 2p and neuroblastoma
82. Trisomy 2p: Analysis of unusual phenotypic findings
83. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients
84. Identification of MYCN copy number heterogeneity by direct FISH analysis of neuroblastoma preparations
85. Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma
86. Amplified N-myc in human neuroblastoma cells is often arranged as clustered tandem repeats of differently recombined DNA
87. The DDX1 gene maps within 400 kbp 5′ to MYCN and is frequently coamplified in human neuroblastoma
88. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma
89. Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma
90. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma
91. The homeobox gene MEIS1 is amplified in IMR-32 and highly expressed in other neuroblastoma cell lines
92. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
93. Amplification of N-myc oncogene in stage II and IVS neuroblastomas may be a prognostic indicator
94. Clinical implications of oncogene activation in human neuroblastomas
95. Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: Results of the French NBL 90 Study. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP)
96. Biological characteristics of N-myc amplified neuroblastoma in patients over one year of age
97. Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture
98. Sustained expression of the human protooncogene MYCN rescues rat embryo cells from senescence
99. In vivo regulation of single copy and amplified N-myc in human neuroblastoma cells
100. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma
101. The N-Myc oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in human neuroblastoma cells
102. The mycN/max protein complex in neuroblastoma. Short review
103. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN
104. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma
105. Neoplastic transformation by the human gene N-myc
106. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: Evidence for induction of autocrine growth factor activity
107. Targeted expression of MYCN causes neuroblastoma in transgenic mice
108. MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells
109. MycN sensitizes neuroblastoma cells for drug-induced apoptosis
110. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV
111. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition
112. Apoptotic cell death induced by c-myc is inhibited by bcl-2
113. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN
114. Human neuroblastomas and abnormalities of chromosomes 1 and 17
115. Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells
116. 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines
117. Molecular cytogenetic analysis of 1;17 translocations in neuroblastoma
118. Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas
119. Promiscuous translocations of chromosome arm 17q in human neuroblastomas
120. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization
121. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization
122. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma
123. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma
124. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group
125. 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group
126. Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24
127. Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines
128. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma
129. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma
130. Nm23-H1 mutation in neuroblastoma
131. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors
132. Chromosomal imbalance maps of malignant solid tumors: A cytogenetic survey of 3185 neoplasms
133. Neuroblastoma in a boy with MCA/MR syndrome, deletion 11q, and duplication 12q
134. High incidence of constitutional balanced translocations in neuroblastoma
135. Genetics of familial neuroblastoma: Long-range studies
136. An increased NM23H1 copy number may be a poor prognostic factor independent of LOH on 1p in neuroblastomas
137. Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas
138. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas
139. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma
140. Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma
141. Representational difference analysis and loss of heterozygosity studies detect 3p deletions in neuroblastoma
142. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicates a tumour-suppressor locus distal to the FHIT gene
143. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3
144. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours
145. Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: A comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening
146. CpG island methylator phenotype in colorectal cancer
147. 1q23 gain is associated with progressive neuroblastoma resistant to aggressive treatment
148. Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locus
149. Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: Evidence for two deleted regions
150. Deletion of chromosome 11 and of 14q sequences in neuroblastoma
151. Frequent loss of heterozygosity on chromosome 14q in neuroblastoma
152. Analysis of loss of heterozygosity at 16p12-p13 (familial neuroblastoma locus) in 470 neuroblastomas including both sporadic and mass screening tumors
153. Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13
154. Sensitive and reliable detection of genomic imbalances in human neuroblastomas using comparative genomic hybridisation analysis